Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche 2025 results
Roche 2025 results Basel, 29 January 2026
Slide 4: Group
Group Thomas Schinecker Chief Executive Officer
Slide 5: FY 2025 performance, next innovation cycle, outlook
FY 2025 performance Delivering the next innovation cycle Outlook
Slide 6: 2025: Strong financial and pipeline performance
2025: Strong financial and pipeline performance FY results at CER ▪ Group sales growth +7%, +9% for Pharma and +2% for Diagnostics (despite China healthcare pricing reforms) ▪ Strong operating performance with Core OP +13% and Core OP margin +1.9%p; Core EPS +11% ▪ Full year LOE impact was CHF -0.7b
Slide 7: 2025: Consistent strong growth
2025: Consistent strong growth Diagnostics impacted by healthcare pricing reforms in China in 2025 Group sales growth %CER +15% +10% +9% +9% +9% +9% +8% +8% +6% +6% +5% +2% +1% +2% +1% 0% COVID-19 pandemic Pandemic phase out Post-pandemic Base business: +1%* Base business: +8%* Business growth: +8%*
Slide 8: 2025: Continued strong Pharma sales driving Group growth
2025: Continued strong Pharma sales driving Group growth Diagnostics excluding China grew +7% at CER FY 2025 FY 2024 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 47.7 46.2 3 9 Diagnostics Division 13.8 14.3 -3 2 Roche Group 61.5 60.5 2 7 CER: Constant exchange rates (avg. full year 2024)
Slide 9: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio All therapeutic areas delivering strong growth Diagnostics: Molecular Lab and 2025 sales Pathology Lab with strong growth; Core Lab impacted by China healthcare +2% (CHFbn, YoY CER growth) Phesgo: Global conversion rates >50%*; HER2+ BC pricing reforms; excl
Slide 10: Achieved 2025 upgraded guidance
Achieved 2025 upgraded guidance LOE impact of -0.7bn Guidance Results Group sales growth1 Mid single digit sales growth +7% High single digit to low double digit Core Core EPS growth1 +11% EPS growth (from high single digit growth) Dividend outlook Further increase dividend in Swiss francs2 CHF 9.80
Slide 11: Substantial 2025 pipeline progress across all TAs
Substantial 2025 pipeline progress across all TAs 12 positive Phase III readouts unlocking significant upside potential Positive key Phase III readouts 10 NMEs new to Phase III ▪ lidERA in adjuvant ER+ BC NXT007 zosurabalpin giredestrant in hemophilia A in bacterial infections ▪ evERA in 2L+ ER+ mBC
Slide 12: Agreement with the US Government reached
Agreement with the US Government reached Roche portfolio exempt from tariffs and demo projects (GUARD and GLOBE) Implications of the agreement USD 50bn investment in manufacturing, infrastructure, R&D Medicaid rebates 13+1* manufacturing and 15+1* R&D sites in the US 1 Genentech to offer states addi
Slide 13: FY 2025 performance, next innovation cycle, outlook
FY 2025 performance Delivering the next innovation cycle Outlook
Slide 14: Substantial progress made across key initiatives
Substantial progress made across key initiatives R&D Excellence efforts have already translated into a material shift of the portfolio value Key initiatives Key milestones achieved R&D Excellence progress 2020 2022 2023 2024 2025 Introduction of the Bar Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 >60% of
Slide 15: Strong on-market portfolio with no patent cliff ahead
Strong on-market portfolio with no patent cliff ahead Significant upside potential being unlocked in 2025/26; key Ph III readouts 2027 onwards Today’s on-market Pharma portfolio Positive key Ph III readouts in 2025 Next key NMEs expected to to deliver growth until 2028 enabling filings, including 3
Slide 16: Substantial progress on pipeline rejuvenation
Substantial progress on pipeline rejuvenation Prioritization of high-impact projects and strategic business development Portfolio evolution (NME additions / removals) Portfolio value Average peak sales per 8 -8 pipeline project, CHF bn1 81 4 -3 1 FGF21 analog -5 3 -4 in MASH 3 +60% -9 5 -5 3 -2 1 -5
Slide 17: Roche Diagnostics: Key technology launches driving future growth
Roche Diagnostics: Key technology launches driving future growth CGM, Mass Spec and SBX each represent >1bn CHF opportunities Accu-Chek® SmartGuide cobas® i601 Mass Spec AXELIOS (SBX) (2024) (2024) (2026) ▪ 14-day real-time glucose sensor with ▪ First fully integrated IVD platform ▪ World record for
Slide 18: FY 2025 performance, next innovation cycle, outlook
FY 2025 performance Delivering the next innovation cycle Outlook
Slide 19: Sustaining pipeline momentum through 2026
Sustaining pipeline momentum through 2026 10 key Ph III readouts; significant progress in obesity portfolio expected Key regulatory milestones Key Phase III readouts Phase II readouts in obesity giredestrant filing giredestrant in 1L ER+/HER2- mBC CT-388 (Ph III to be initiated) in adjuvant ER+/HER2
Slide 20: Future growth outlook: Up to 19 NMEs with launch potential by 2030
Future growth outlook: Up to 19 NMEs with launch potential by 2030 First post Bar NMEs expected to readout in 2027; peak sales assumptions for fenebrutinib and sefaxersen raised 0.5-1bn peak sales 1-2bn peak sales afimkibart 2-3bn peak sales >3bn peak sales CT-388 IBD, AtD, RA, MASH Obesity +/- T2D
Slide 21: 2026 guidance
2026 guidance LOE impact of roughly CHF 1bn expected for 2026 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 2025); LOE: Loss of exclusi
Slide 22: Finance
Finance Alan Hippe Chief Financial Officer
Slide 23: Results, cash & balance sheet, currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 24: 2025: Group performance
2025: Group performance Sales increase of +7% and Core EPS increase of +11% 2025 2024 Change in % CHFm CHFm CHF CER Sales 61,516 60,495 +2 +7 Core operating profit 21,833 20,823 +5 +13 as % of sales 35.5 34.4 Core net income 16,575 16,011 +4 +11 as % of sales 26.9 26.5 Core EPS (in CHF) 19.46 18.80
Slide 25: 2025: Group sales growth at +7%
2025: Group sales growth at +7% Continued strong Pharma sales driving Group growth +7% at CER CHFm +871 +4,792 -745 -579 -3,318 60,495 61,516 FY 2024 Pharma LOE Dia China Fx FY 2025 (excl. LOE) (excl. China) healthcare pricing reforms CER: Constant exchange rates (avg. full year 2024); LOE: Loss of
Slide 26: 2025: Group Core operating profit
2025: Group Core operating profit Core operating profit higher by +13%, driven by higher sales and effective cost management 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 61,516 +4,339 7% Other revenue 1,840 +15 1% Cost of sales -15,864 -1,136 7% R&D -12,243 +332 -3% SG&A -13,838 -649 5% OOI&E
Slide 27: 2025: Core operating profit and margin
2025: Core operating profit and margin % of sales 47.7% 49.2% 35.5% +1.9%p¹ 34.4% +1.9%p¹ +13%¹ 16.8% 14.4% CHFm +13%¹ 23,440 21,833 22,014 -1.1%p¹ 20,823 -4%¹ 2024 2025 2,402 1,998 Roche Group Pharma Division Diagnostics Division Note: Group Core operating profit includes -3.6bn from Corporate (-3.
Slide 28: 2025: Core net financial result
2025: Core net financial result Improvement mainly driven by lower losses from foreign exchange results (Other) CHFm ▪ Net financial result worsened by -60m / +5% at CER ▪ Interest expenses1 improved by +10m / -1% at CER -1,477 -1,610 +69 +199 -88 -47 FY 2024 Equity Net interest Interest Other FY 20
Slide 29: 2025: Core tax rate
2025: Core tax rate Higher tax rate mainly due to changes in profit mix and lower impact from resolution of tax disputes +1.9%p -0.9%p 18.6% +1.4%p -1.4%p 16.7% 19.5% 18.1% Effective Resolution of Effective tax Profit mix Effective tax Resolution of Effective tax rate tax disputes rate FY 2024 and o
Slide 30: 2025: Core EPS
2025: Core EPS Increase in operations partially offset by a higher tax rate and lower gains on product disposals +11.0% -1.2%p -0.3%p -2.8%p 21.45 +15.8%p -0.5%p 19.33 FY 2024 Operations1 Product disposals Financial Effective tax All other effects FY 2025 & disposal of income/expense rate change sub
Slide 31: 2025: Non-core and IFRS income
2025: Non-core and IFRS income Non-core items lower vs. PY due to lower impairment of goodwill 2025 2024 Var. at Change in % CHFm CHFm CERm CHF CER Core operating profit 21,833 20,823 +2,714 +5 +13 Global restructuring plans -2,164 -1,891 -344 Amortisation of intangible assets -669 -736 +44 1 Impair
Slide 32: Results, cash & balance sheet, currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 33: 2025: Group operating free cash flow
2025: Group operating free cash flow OFCF down by -12% driven by NWC movement (higher year end receivables) and investments in IA (Zealand Pharma) CHFm +1,429 -2,863 -420 -645 -1,547 20,209 OFCF down by -12%/ -2,499m at CER 17,710 16,163 FY 2024 OP, net of cash NWC Investments Investments FY 2025 Fo
Slide 34: 2025: Operating free cash flow and margin
2025: Operating free cash flow and margin % of sales 48.3% 47.7% 49.2% 41.0% 33.3% 26.3% 35.5% +1.9%p¹ -6.8%p¹ 34.4% -6.1%p¹ 12.1% +1.9%p¹ 4.9% +13%¹ 16.8% 14.4% CHFm +13%¹ -5.9%p¹ 23,440 21,833 22,288 22,014 -6%¹ -1.1%p¹ 20,823 20,121 19,539 -12%¹ 16,163 -48%¹ -4%¹ 1,734 2024 2024 2025 2025 2,402 6
Slide 35: 2025: Group net debt development
2025: Group net debt development Net debt lower by CHF 1.2bn vs. YE 2024 Free cash flow CHF +11.8 CHFbn Dividends paid -8.4 -4.4 Trans. own eq. inst. -1.0 M&A & all. trans. -3.1 Curr. transl. & oth. +1.8 Taxes -3.1 Treasury -1.2 -17.3 +16.2 -16.2 -10.7 Net debt Operating Non-operating Dividends, M&A
Slide 36: Balance sheet 31 December 2025
Balance sheet 31 December 2025 Equity ratio at 38% (31 Dec 2024: 36%) % change in CER % change in CER CHFbn vs. 31 Dec 2024 vs. 31 Dec 2024 Cash and 101.8 100.7 +7% 101.8 100.7 +7% marketable 17.3 15.5 -5% securities 17% Current 27.0 28.0 15% Other 27% 28% +12% liabilities current 22.7 23.3 23% +11%
Slide 37: Results, cash & balance sheet, currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 38: 2025: Currency impact and outlook
2025: Currency impact and outlook USD / CHF In 2025 impact1 is (%p): +3% -3% -4% -6% Q1 Q2 Q3 Q4 0.90 0.89 0.88 0.88 Sales +1 -8 -7 -7 0.87 0.86 0.84 0.83 Q1 HY YTD FY Sep 0.91 0.90 0.88 0.84 0.83 0.82 0.80 0.81 0.80 0.80 0.80 0.80 Sales +1 -3 -5 -5 Monthly avg fx rates 2025 Average YTD 2025 Average
Slide 39: 2025: Core EPS
2025: Core EPS Core EPS 2025 of CHF 19.83 is basis for Core EPS outlook 2026 at CER CHF 19.83 19.46 +0.37 Core EPS 2025 2025 foreign Core EPS 2025 basis as reported exchange losses: for outlook core EPS Core EPS impact growth 2026 at CER CER: Constant exchange rates (avg. full year 2025); EPS: Earni
Slide 40: 2026 guidance
2026 guidance LOE impact of roughly CHF 1bn expected for 2026 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 2025); LOE: Loss of exclusi
Slide 41: Results, cash & balance sheet, currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook Upcoming changes
Slide 42: Prospective change in income statement presentation 2026
Prospective change in income statement presentation 2026 Further centralization of functions with global accountability: Legal costs to be reported as SG&A Corporate Changes in Income Statement presentation ▪ Implementation effective 1 January 2026: Most legal costs reported as SG&A under Corporate
Slide 43: Pharmaceuticals Division
Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals
Slide 44: Roche Pharma: Key priorities
Roche Pharma: Key priorities Sustain momentum through commercial excellence, key launches and portfolio rejuvenation Maximize on-market portfolio Deliver key launches Progress post Bar NMEs Current on-market portfolio to deliver Upcoming launches to support Prepare entry into broad scale DAs, growth
Slide 45: 2025: Pharmaceuticals sales
2025: Pharmaceuticals sales Continued strong growth across all regions FY 2025 FY 2024 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 47,669 46,171 3 9 United States 25,355 24,774 2 8 Europe 9,164 8,832 4 5 Japan 2,882 2,874 0 5 International 10,268 9,691 6 ##### 14 CER: Constant exchange ra
Slide 46: 2025: Pharmaceuticals Core operating profit
2025: Pharmaceuticals Core operating profit Core operating profit outgrowing sales with +13%, driven by higher sales and effective cost management 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 47,669 +4,047 9% Other revenue 1,782 -14 -1% Cost of sales -8,678 -624 7% R&D -10,399 +293 -3% SG&A -7
Slide 47: 2025: Diversified set of key growth drivers
2025: Diversified set of key growth drivers Phesgo, Xolair, Ocrevus, Hemlibra, Vabysmo, and Polivy driving growth Phesgo 48% Xolair 32% Ocrevus 9% Hemlibra 11% Vabysmo 12% Polivy 38% Xofluza 184% Evrysdi 13% Elevidys 84% Columvi 75% Gazyva 14% Itovebi >500% Tecentriq 3% Alecensa 6% Enspryng 23% Luns
Slide 48: Oncology growing +2% driven by the HER2+ franchise
Oncology/Hematology Oncology growing +2% driven by the HER2+ franchise Giredestrant: evERA US filing achieved and positive Ph III (lidERA) in adj. ER+/HER2- BC presented at SABCS Q4 update Itovebi Avastin CHF 113m / +* ▪ Phesgo: Global conversion rate climbing to 54%** CHF 973m / -17% Others ▪ Perje
Slide 49: Giredestrant: Positive Ph III (lidERA) results in adjuvant ER+/HER2- BC
Oncology/Hematology Giredestrant: Positive Ph III (lidERA) results in adjuvant ER+/HER2- BC First and only oral SERD to show superior iDFS in the adjuvant setting Ph III (lidERA) iDFS results in adjuvant ER+/HER2- BC1 100 Giredestrant SOC ET n = 2084 n = 2086 80 100 97.7% 94.6% Events, n (%) 140 (6.
Slide 50: Giredestrant: Next-gen SERD with potential to replace SOC ET
Oncology/Hematology Giredestrant: Next-gen SERD with potential to replace SOC ET in ER+ BC Complemented by a portfolio of potentially BIC molecules allowing combinations Potential to redefine treatment paradigm in ER+ BC Differentiated molecules targeting key signaling nodes Low risk Medium risk Hig
Slide 51: Polivy US patient share in 1L DLBCL reaching 36%
Oncology/Hematology Polivy US patient share in 1L DLBCL (IPI 0-5) reaching 36% Lunsumio SC in 3L+ FL achieved US and EU approval Q4 update Columvi Lunsumio CHF 288m / +75% CHF 114m / +68% ▪ Hemlibra: Continued global growth; increasing adoption in non- PiaSky inhibitor patients MabThera/Rituxan CHF
Slide 52: Ocrevus: >50% of global growth in Q4 driven by SC
Neurology Ocrevus: >50% of global growth in Q4 driven by SC First positive Ph III results for fenebrutinib in RMS (FENhance 2) and PPMS (FENtrepid) Q4 update Elevidys Others ▪ Ocrevus: >17,500 patients on Ocrevus SC globally CHF 341m / +84% CHF 362m / -3% ▪ US: >60% of SC volume coming from communit
Slide 53: Fenebrutinib: Potential for FIC and BIC in both RMS and PPMS
Neurology Fenebrutinib: Potential for FIC and BIC in both RMS and PPMS First and only BTKi with positive results in Ph III trials in RMS (FENhance 2) and PPMS (FENtrepid) Designed to control relapsing and progressive biology Optimized PK profile1 Free plasma concentration of BTKis fenebrutinib BTKi
Slide 54: Xolair strong growth momentum driven by food allergy
Immunology Xolair strong growth momentum driven by food allergy Gazyva: Positive Ph III results in SLE (ALLEGORY) and INS (INShore); EU approval for LN achieved Q4 update ▪ Xolair: Strong food allergy launch with >100k patients treated Others CHF 898m / -1% Actemra ▪ Biosimilar launch expected H2 20
Slide 55: Vabysmo continued strong global growth
Ophthalmology Vabysmo continued strong global growth Vamikibart in UME and Enspryng in TED to be filed in 2026 Q4 update Luxturna CHF 41m / +146% Susvimo ▪ Vabysmo: Continued market share gains across early launch Lucentis CHF 9m / +132% countries and ongoing global expansion CHF 58m / -58% ▪ US bra
Slide 56: CVRM pipeline: Ph III enabling data for five NMEs expected in 2026
Cardiovascular, Renal & Metabolism CVRM pipeline: Ph III enabling data for five NMEs expected in 2026 Positive Ph II (103) for CT-388 in obesity w/o T2D: Placebo-adjusted WL of 22.5% at 48w (efficacy estimand) achieved Clinical development Q4 update ▪ CT-388 in obesity without T2D: Positive Ph II (1
Slide 57: 2026: Key newsflow outlook
2026: Key newsflow outlook* Giredestrant + everolimus (post CDKi ER+/HER2- mBC) filed in US Compound Indication Milestone giredestrant adjuvant ER+/HER2- early BC US/EU filing giredestrant + everolimus post CDKi ER+/HER2- mBC EU filing/US approval Gazyva SLE US/EU filing Gazyva INS US/EU filing Ensp
Slide 58: Diagnostics Division
Diagnostics Division Matt Sause CEO Roche Diagnostics
Slide 59: 2025: Diagnostics sales
2025: Diagnostics sales Diagnostics growing at +2%, impacted by China healthcare pricing reforms CER: Constant exchange rates (avg. full year 2024) 59
Slide 60: 2025: Diagnostics highlights
2025: Diagnostics highlights Diagnostics growing at +2%, impacted by China healthcare pricing reforms CHFbn YoY CER growth ▪ Immunodiagnostics (-3%) Core Lab 0% ▪ Clinical chemistry (+7%) ▪ Blood screening (+3%) Molecular Lab +4% ▪ Infectious diseases (+1%) Near Patient ▪ BGM (-2%) -3% Care ▪ Liat P
Slide 61: 2025: Diagnostics regional sales
2025: Diagnostics regional sales Strong growth in Latin America, North America, and EMEA North America +9% EMEA ~32% of divisional sales +6% ~36% of divisional sales Asia Pacific Latin America -12% +11% ~24% of divisional sales ~8% of divisional sales Growth rates at constant exchange rates (avg. fu
Slide 62: 2025: Diagnostics Core operating profit
2025: Diagnostics Core operating profit Core operating profit lower by -4% driven by China healthcare pricing reforms 2025 2025 vs. 2024 CHFm Abs. CERm CER growth Sales 13,847 +292 2% Other revenue 58 +30 100% Cost of sales -7,186 -512 7% R&D -1,844 +39 -2% SG&A -2,923 +73 -2% OOI&E 46 -23 -32% Core
Slide 63: cobas i 601 Mass Spectrometry wave 1 menu CE mark
cobas® i 601 Mass Spectrometry wave 1 menu CE mark Mass spec assay menu expansion to cover the vast majority of routine testing demand cobas® i 601 Mass Spectrometry wave 1 menu Market needs and opportunity ▪ Market Opportunity: The current clinical mass spectrometry market is CHF 3bn, composed of l
Slide 64: Elecsys Dengue Ag CE mark
Elecsys® Dengue Ag CE mark Highly reliable automated serology assay for the detection of acute dengue infection Elecsys® Dengue Ag test Market needs and opportunity ▪ High Burden: Dengue is the most common mosquito-borne viral disease globally with an estimated 390m infections annually1 ▪ Difficult
Slide 65: cobas BV/CV CE mark
cobas® BV/CV CE mark Important molecular menu gap fill to expand in the fast-growing molecular STI segment Expanding STI menu Market opportunity ▪ The sexual health diagnostics market is valued at CHF 1.1bn with a yearly growth rate of 11%1 ▪ Vaginitis is the primary growth driver in the STI segment
Slide 66: cobas liat Bordetella panel CE mark and FDA clearance
cobas® liat Bordetella panel CE mark and FDA clearance Rapid and accurate detection of Bordetella to enable early intervention and reduce potential complications cobas® liat assay menu Market needs and opportunity ▪ High Burden: Pertussis causes 24.1 million cases annually, resulting cobas® liat Bor
Slide 67: Diagnostics key launches 2026
Diagnostics key launches 2026 Area Product Description Market Status Molecular Novel high-throughput solution for ultra-rapid, scalable, and flexible sequencing powered by Sequencing by Systems Lab AXELIOS Sequencing Solution Expansion (SBX) technology Global Non-invasive blood-based biomarker to en
Slide 68: Invitation to Diagnostics Day 2026
Invitation to Diagnostics Day 2026 Roche Diagnostics Day: 12 May London / hybrid event 14:00 - 16:45 CEST / 13:00 - 15:45 BST 08:00 - 10:45 am EDT / 05:00 - 07:45 am PDT 68
Slide 69: Doing now what patients need next
Doing now what patients need next
Slide 70: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 71: Changes to the development pipeline
Changes to the development pipeline Q4 2025 update New to phase I New to phase II New to phase III New to registration 5 NMEs: 1 AI: 1 NME: 1 NME (US): RG6913 NME – DME RG6631 afimkibart (anti-TL1A) - rheumatoid RG7935 prasinezumab - Parkinson’s RG6171 giredestrant + everolimus - RG6496 HTT SNP ASO
Slide 72: Roche Group development pipeline
Roche Group development pipeline Phase I (40 NMEs + 6 AIs) Phase II (15 NMEs + 7 AIs) RG6026 Columvi monotherapy + combos heme tumors RG6382 CD19 x CD3 SLE RG6171 giredestrant endometrial cancer RG6076 englumafusp alfa combos heme tumors RG6377 Anti-leukocyte trafficking antibody IBD RG6180 autogene
Slide 73: Roche Group development pipeline
Roche Group development pipeline Phase III (10 NMEs + 27 AIs) Registration US & EU (1 NME + 1AI) RG3502 Kadcyla + T HER-2+ eBC high-risk RG6149 astegolimab COPD RG6171 giredestrant + everolimus+ post-CDK4/6 ER+/HER2- BC RG6013 Hemlibra Type 3 VWD RG62992 sefaxersen (ASO factor B) IgA nephropathy RG7
Slide 74: Expected regulatory submissions
autogene cevumeran RG6180 Expected regulatory submissions* solid tumors divarasib + New Molecular Entities: Lead and additional indications RG6330 pembrolizumab 1L NSCLC NXT007 prasinezumab RG6512 RG7935 hemophilia Parkinson’s New Molecular Entity (NME) Cardiovascular, Renal & Metabolism flizasertib
Slide 75: Expected regulatory submissions
Expected regulatory submissions* Marketed products: Additional indications PiaSky New Molecular Entity (NME) Cardiovascular, Renal & Metabolism RG6107 Additional Indication (AI) Neurology aHUS Oncology / Hematology Ophthalmology Immunology Other Itovebi + fulvestrant RG6114 post CDKi HR+ PIK3CA-mut.
Slide 76: Major pending approvals 2025
Major pending approvals 2025 US EU China Japan-Chugai giredestrant + everolimus Susvimo Polivy + chemo Lunsumio + Polivy RG6171 post-CDK4/6 ER+/HER2- BC RG6321 wAMD RG7596 r/r DLBCL RG7828 2L+ DLBCL Filed Dec 2025* Filed July 2025 Filed May 2025 Filed May 2025 Tecentriq Alecensa RG7446 ctDNA+ high-r
Slide 77: Major granted approvals 2025
Major granted approvals 2025 US EU China Japan-Chugai TNKase Columvi + chemo Lunsumio Tecentriq RG3625 stroke RG6026 2L DLBCL RG7828 3L+ FL RG7446 Alveolar Soft Part Sarcoma Feb 2025 April 2025 Dec 2024 Feb 2025 Susvimo Xofluza Itovebi + palbociclib + fulvestrant Elevidys RG6321 DME RG6152 influenza
Slide 78: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 79: Marketed products development programmes
Marketed products development programmes Oncology / Hematology Neurology Immunology Ophthalmology CVRM RG7853 Alecensa RG6356 Elevidys RG7159 Gazyva RG6168 Enspryng RG6114 Itovebi RG6168 Enspryng RG7828 Lunsumio RG6321 Susvimo RG3502 Kadcyla RG7916 Evrysdi RG7716 Vabysmo RG7446 Tecentriq RG6152 Xofl
Slide 80: Alecensa (alectinib)
Alecensa (alectinib, RG7853) CNS-active inhibitor of anaplastic lymphoma kinase Indication Locally advanced, unresectable, stage III NSCLC Phase III Phase/study HORIZON-01 # of patients N=70 ▪ ARM A: Alecensa 600mg BID Oncology/Hematology ▪ ARM B: durvalumab 1500 Q4W Design ▪ Progression-free surviv
Slide 81: Itovebi (inavolisib)
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor Indication PIK3CA-mutant HR-positive metastatic breast cancer (mBC) post CDKi HR-positive PIK3CA-mutant breast cancer Phase III Phase III Phase/study INAVO120 INAVO121 # of patients N=320 N=400 ▪ ARM A:
Slide 82: Itovebi (inavolisib)
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor 1L endocrine-sensitive PIK3CA-mutated HR+, HER2-, advanced breast Indication 1L HER2-positive PIK3CA mutant metastatic breast cancer (mBC) cancer Phase III Phase III Phase/study INAVO122 INAVO123 # of pa
Slide 83: Kadcyla (trastuzumab emtansine)
Kadcyla (trastuzumab emtansine, RG3502) First ADC for HER2-positive breast cancer HER2-positive early breast cancer (BC) Indication high-risk patients Phase III Phase/study ASTEFANIA # of patients N=1150 ▪ ARM A: Kadcyla plus Tecentriq Oncology/Hematology Design ▪ ARM B: Kadcyla plus placebo ▪ Invas
Slide 84: Tecentriq lung cancer
Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy – lung cancer Indication Periadjuvant NSCLC 1L maintenance extensive-stage SCLC Phase III Phase III Phase/study IMpower030 IMforte1 # of patients N=450 N=450 Oncology/Hematology ▪ ARM A: Tecentriq plus platinum-based chemotherapy ▪ ARM
Slide 85: Tecentriq urothelial carcinoma
Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy – urothelial carcinoma ctDNA+, high-risk muscle-invasive Indication bladder cancer (MIBC) Phase III Phase/study IMvigor011 # of patients N=240 ARM A: Tecentriq monotherapy Oncology/Hematology ▪ ▪ ARM B: Placebo Design ▪ Disease-free su
Slide 86: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory Non-Hodgkin’s lymphoma (NHL) Phase/study Phase I Phase I # of patients N=700 N=18-36 Cohort 1: Single-agent dose escalation study Columvi SC ▪ Initial dose escalatio
Slide 87: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT-ineligible DLBCL Phase/study Phase Ib # of patients N=112 ▪ ARM A: Columvi IV plus CELMoD (CC-220 and CC-99282) Oncology/Hematology ▪ ARM B: Lunsumio SC plus CELMoD (CC-220 and CC-
Slide 88: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT-ineligible DLBCL 1L DLBCL fit (IPI 2-5) Phase III Phase III Phase/study STARGLO SKYGLO # of patients N=270 N=1130 ▪ ARM A: Columvi plus gemcitabine and oxaliplatin, followed by up
Slide 89: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory mantle cell lymphoma (MCL) Phase III Phase/study GLOBRYTE # of patients N=182 ▪ ARM A: Columvi monotherapy Oncology/Hematology ▪ ARM B: Bendamustine + rituximab or r
Slide 90: Lunsumio (mosunetuzumab)
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 3L+ FL, 3L+ DLBCL & other relapsed or refractory NHL Phase/study Phase I/II # of patients N=713 ▪ Dose escalation of Lunsumio monotherapy and in combination with Tecentriq ▪ Expansion
Slide 91: Lunsumio (mosunetuzumab)
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication FL 2L+ FL Relapsed or refractory CLL Phase III Phase/study Phase Ib/II Phase Ib/II CELESTIMO # of patients N=183 N=474 N=137 Non-Randomized: ▪ ARM A: Lunsumio plus lenalidomide ▪ Lunsu
Slide 92: Lunsumio (mosunetuzumab)
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT ineligible DLBCL Relapsed or refractory LBCL & MCL Phase III Phase/study Phase Ib/II SUNMO # of patients N=222 N=235 ▪ ARM A: Lunsumio plus Polivy Dose escalation of Lunsumio p
Slide 93: Polivy (polatuzumab vedotin)
Polivy (polatuzumab vedotin, RG7596) ADC targeting CD79b to treat B cell malignancies Indication 1L DLBCL Phase III Phase/study POLARIX # of patients N=879 Oncology/Hematology ▪ ARM A: Polivy plus R-CHP ▪ ARM B: R-CHOP Design ▪ Progression-free survival Primary endpoint ▪ Data presented at ASH 2021
Slide 94: Hemlibra (emicizumab)
Hemlibra (emicizumab, RG6013) Factor VIII mimetic for treatment of hemophilia A Indication Type 3 Von Willebrand disease (VWD) Phase III Phase/study WILL-EMI # of patients N=66 Open-label in participants aged 2 years and above diagnosed with Type 3 von Willebrand disease (VWD) on prior SOC on demand
Slide 95: PiaSky (crovalimab)
PiaSky (crovalimab, RG6107, SKY59) A humanized monoclonal antibody against complement C5 Atypical hemolytic uremic syndrome (aHUS) Atypical hemolytic uremic syndrome (aHUS) Indication - adults - paediatric Phase III Phase III Phase/study COMMUTE-a COMMUTE-p # of patients N=90 N=35 Single-arm study o
Slide 96: Elevidys
Elevidys (delandistrogene moxeparvovec, RG6356, SRP-9001) rAAVrh74.MHCK7.Micro-dystrophin gene therapy Indication Duchenne muscular dystrophy (DMD) Phase II Phase/study ENVOL # of patients N=21 Neurology Open label single arm study in 0 to <4 year old DMD boys who will receive a single intravenous (
Slide 97: Enspryng (satralizumab)
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Myelin oligodendrocyte glycoprotein antibody Indication Autoimmune encephalitis (AIE) Duchenne Muscular Dystrophy (DMD) disease (MOG-AD) Phase III Phase III Ph II Phase/study METEOROID CIELO SHIELD DMD # of patie
Slide 98: Evrysdi (risdiplam)
Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier Indication Spinal muscular atrophy (SMA) Phase II Phase II Phase/study RAINBOWFISH JEWELFISH # of patients N=25 N=174 ▪ Infants aged from birth to 6 weeks who have been genetically ▪ Adult and pediatric patients with previously treated SMA type
Slide 99: Gazyva (obinutuzumab)
Gazyva (obinutuzumab, RG7159) Humanized anti-CD20 monoclonal antibody; immunology development program Indication Lupus nephritis Childhood onset idiopathic nephrotic syndrome* Phase III Phase III Phase/study REGENCY INShore # of patients N=252 N=80 ▪ ARM A: Gazyva 1000mg IV (6 doses through Week 52)
Slide 100: Gazyva (obinutuzumab)
Gazyva (obinutuzumab, RG7159) Humanized anti-CD20 monoclonal antibody; immunology development program Indication Systemic lupus erythematosus (SLE) Membranous nephropathy Phase III Phase III Phase/study ALLEGORY MAJESTY # of patients N=300 N=140 ARM A: Gazyva 1000mg IV on Day 1 and Weeks 2, 24 and 2
Slide 101: Lunsumio in SLE
Lunsumio (mosunetuzumab, RG7828, CD20 x CD3) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Systemic lupus erythematosus (SLE) Phase/study Phase I # of patients N=15 ▪ ARM A: Lunsumio SC on either Day 1 or on Days 1 and 8 Immunology ▪ ARM B: Fractionated (divided)
Slide 102: Enspryng in thyroid eye disease
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Thyroid eye disease Phase III Phase III Phase/study SatraGO-1 SatraGO-2 # of patients N=120 N=120 ▪ ARM A: Enspryng at weeks 0, 2, 4 (loading doses) and maintenance doses ▪ ARM A: Enspryng at weeks 0,
Slide 103: Susvimo (PDS)
Susvimo (PDS, RG6321) First eye implant to achieve sustained delivery of a biologic medicine Indication Wet age-related macular degeneration (wAMD) Phase III Phase II+III extension Phase IIIb Phase/study Archway Portal Velodrome # of patients N=418 N=1,000 N=442 ▪ ARM A: PDS 100mg/mL Q24W ▪ Ex-LADDE
Slide 104: Susvimo (PDS)
Susvimo (PDS, RG6321) First eye implant to achieve sustained delivery of a biologic medicine Diabetic retinopathy (DR) without Indication Diabetic macular edema (DME) center-involved diabetic macular edema (DME) Phase III Phase III Phase/study Pagoda Pavilion # of patients N=634 N=174 ▪ ARM A: Intra
Slide 105: Vabysmo (faricimab)
Vabysmo (faricimab, RG7716) Bispecific antibody for the eye which targets and inhibits two signaling pathways (Ang-2 and VEGF-A) Indication Myopic choroidal neovascularization (CNV) Phase III Phase/study POYANG # of patients n=280 Ophthalmology ▪ ARM A: Vabysmo 6.0 mg Q4W PRN ▪ ARM B: Ranibizumab 0.
Slide 106: Xofluza (baloxavir marboxil)
Xofluza (baloxavir marboxil, RG6152, S-033188) Small molecule, novel CAP-dependent endonuclease inhibitor Indication Influenza Phase III Phase III Phase IIIb Phase/study miniSTONE 1 (0-1 year old) miniSTONE 2 (1- <12 years old ) CENTERSTONE # of patients N=30 N=176 N=3,160 Healthy pediatric patients
Slide 107: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 108: Roche Pharma global development programmes
Roche Pharma global development programmes Oncology / Hematology Neurology Immunology Ophthalmology CVRM RG6330 Divarasib RG6237 Emugrobart RG6299 Sefaxersen RG6179 Vamikibart RG6640 CT-388 RG6171 Giredestrant RG7845 Fenebrutinib RG6631 Afimkibart RG6652 CT-996 RG6512 NXT007 RG7935 Prasinezumab RG66
Slide 109: Divarasib (KRAS G12C inhibitor)
Divarasib (KRAS G12C inhibitor, RG6330, GDC-6036) A potent, orally available, and selective inhibitor of the KRAS G12C mutant protein Indication 1L NSCLC 2L NSCLC 1L NSCLC Phase Ib/II Phase III Phase III Phase/study KRASCENDO 170 KRASCENDO 1 KRASCENDO 2 # of patients N=60 N=320 N=600 ▪ Cohort A: Com
Slide 110: Divarasib (KRAS G12C inhibitor)
Divarasib (KRAS G12C inhibitor, RG6330, GDC-6036) A potent, orally available, and selective inhibitor of the KRAS G12C mutant protein Indication 1L metastatic colorectal cancer (mCRC) Phase Ib Phase/study INTRINSIC # of patients Modular design Single arm studies: ▪ Cohort H: divarasib + Avastin + FO
Slide 111: Giredestrant (SERD)
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator ET resistant ER+/HER2-negative breast cancer Indication Adjuvant ER-positive breast cancer (BC) 1L ER-positive metastatic breast cancer (mBC) (BC) Phase III Phase III Phase III Phase/study lidERA Breast
Slide 112: Giredestrant (SERD)
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator post-CDK4/6 ER-positive/HER2-negative 1L ER-positive/HER2-positive breast cancer Indication Grade 1 endometrial cancer breast cancer (BC) (BC) Phase III Phase III Phase II Phase/study evERA heredERA end
Slide 113: NXT007 (FIXa x FX)
NXT007 (FIXa x FX, RG6512) Bispecific antibody which targets Factor IXa and Factor X Indication Severe or Moderate Hemophilia A Phase I/II Phase/study (multiple-ascending dose) # of patients N=40 Oncology/Hematology ▪ Two loading doses of NXT007 SC (Q2W) followed by Q4W maintenance dosing Design ▪ S
Slide 114: Emugrobart
Emugrobart (RG6237, GYM 329) Recycling and antigen-sweeping monoclonal anti-latent myostatin antibody Indication Facioscapulohumeral Muscular Dystrophy (FSHD) Spinal muscular atrophy (SMA) Phase II Phase II/III Phase/study MANOEUVRE MANATEE1 # of patients N=48 N=259 ▪ 4w baseline movement data colle
Slide 115: Emugrobart
Emugrobart (RG6237, GYM 329) Recycling and antigen-sweeping monoclonal anti-latent myostatin antibody Indication Obesity Phase II Phase/study Phase Ib GYMINDA # of patients N=30-36 N=234 ▪ Cohort A (n=15-18): Single dose emugrobart 50mg SC ▪ 48w DB Tx period: ▪ Cohort B (n=15-18): Multiple dosing 18
Slide 116: Fenebrutinib in RMS
Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase Indication Relapsing multiple sclerosis (RMS) Phase III Phase III Phase II (Biomarker study) Phase/study FENhance 1 FENhance 2 FENopta # of patients N=746 N=751 N=109 ARM A: Fenebrutinib twice daily
Slide 117: Fenebrutinib in PPMS
Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase Indication Primary progressive multiple sclerosis (PPMS) Phase III Phase/study FENtrepid # of patients N=985 Neurology ▪ ARM A: Fenebrutinib twice daily oral ▪ ARM B: Ocrevus 2x300mg IV Q24W Design ▪
Slide 118: Prasinezumab
Prasinezumab (anti-αSynuclein; RG7935) Anti-alpha-synuclein antibody under investigation for Parkinson’s disease Indication Early-stage Parkinson's disease PASADENA PADOVA PARAISO Phase/study Phase II Phase IIb Phase III # of patients 316 586 N=900 ▪ PART 1: ▪ ARM A: Prasinezumab IV Q4W ▪ ARM A: Pra
Slide 119: Tominersen
Tominersen (HTT ASO, RG6042) Antisense oligonucleotide (ASO) targeting human HTT mRNA Indication Huntington’s disease Phase II Phase/study GENERATION HD2 # of patients N=300 Neurology Patients aged 25 to 50 years with prodromal (very early subtle signs of HD) or early manifest HD ▪ ARM A: Tominersen
Slide 120: Trontinemab
Trontinemab (BS-anti-Aβ mAb, RG6102) A novel BrainshuttleTM bispecific 2+1 monoclonal antibody targeting Aβ Prodromal or mild to moderate Alzheimer's Indication Early Alzheimer's Disease Disease Phase III Phase III Phase/study Phase I/II TRONTIER 1 TRONTIER 2 # of patients N=210 N=800 N=800 Neurolog
Slide 121: Sefaxersen
Sefaxersen (ASO factor B, RG6299) Antisense oligonucleotide that targets factor B Indication IgA nephropathy (IgAN) Phase III Phase/study IMAGINATION # of patients N=428 ▪ ARM A: Sefaxersen SC at week 1, 3, 5 following Q4W dosing for 104 weeks ▪ ARM B: Placebo Immunology Design ▪ Change in UPCR at w
Slide 122: Afimkibart in ulcerative colitis
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Indication Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis Phase III Phase III Phase/study AMETRINE-1 AMETRINE-2 # of patients N=400 N=350 ▪ ARM A: Afimkibart IV induction
Slide 123: Afimkibart in Crohn's disease
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Indication Moderate to severe Crohn's Disease Phase III Phase III Phase/study SIBERITE-1 SIBERITE-2 # of patients N=600 N=425 ▪ Treat-through design with no re-randomization after induction ▪ Inductio
Slide 124: Afimkibart
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Metabolic Dysfunction-associated Indication Atopic dermatitis Rheumatoid Arthritis (RA) Steatohepatitis (MASH) Phase II Phase Ib Phase IIb Phase/study VELARITE FIBROLITE dRAvite # of patients N=160 N=
Slide 125: Vamikibart
Vamikibart (anti-IL-6, RG6179) A monoclonal antibody that potently binds interleukin-6 (IL-6) cytokine Indication Uveitic macular edema (UME) Phase III Phase III Phase/study MEERKAT SANDCAT # of patients N=225 N=225 ARM A: Vamikibart low-dose Q4W to week 12, followed by PRN ARM A: Vamikibart low-dos
Slide 126: CT-388
CT-388 (GLP-1/GIP RA, RG6640) Once-weekly subcutaneous injectable dual GLP-1/GIP receptor agonist Overweight/obesity with or without type 2 Overweight/obesity without type 2 Indication Overweight/obesity with type 2 diabetes diabetes diabetes Phase/study Phase I Phase II Phase II # of patients N=129
Slide 127: CT-996
CT-996 (GLP-1 RA, RG6652) Once-daily oral small molecule GLP-1 receptor agonist Overweight/obesity with or without type 2 Indication Obesity without type 2 diabetes Glycaemic control trial with T2D participants diabetes Phase/study Phase I Phase II Phase II # of patients N=118 N=340 N=240 Cardiovasc
Slide 128: CT-868
CT-868 (GLP-1/GIP RA, RG6641) Once-daily subcutaneous injectable dual GLP-1/GIP receptor agonist Indication Type 1 diabetes with BMI ≥ 27 Phase/study Phase II # of patients N=96 Cardiovascular, Renal & Metabolism ▪ ARM A: CT-868 low dose ▪ ARM B: CT-868 medium dose Design ▪ ARM C: CT-868 high dose ▪
Slide 129: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 130: pRED oncology development programs
pRED oncology development programs Molecule Indication Phase # of patients Status CT Identifier Oncology Part I: FPI Q3 2019 Part II: FPI Q3 2020 englumafusp alfa R/R B cell non-Hodgkin’s lymphoma I 498 Part III: FPI Q3 2024 NCT04077723 (CD19-4-1BBL, RG6076) Combination study with Columvi Data prese
Slide 131: pRED neurology development programs
pRED neurology development programs Molecule Indication Phase # of patients Status CT Identifier Neurology ISRCTN16295177 BrainshuttleTM-CD20 (RG6035) Multiple sclerosis I 119 FPI Q3 2021 NCT05704361 nivegacetor (gamma-secretase FPI Q2 2024 Alzheimer's disease II 255 NCT06402838 modulator, RG6289) R
Slide 132: pRED immunology and ophthalmology development programs
pRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Immunology selnoflast* Asthma Ib 60 FPI Q1 2024 (NLRP3i, RG6418) CD19 x CD3 (RG6382) SLE I 70 FPI Q4 2023 NCT05835986 Anti-leukocyte trafficking antibody IBD I FPI Q2 2024 ISRCTN155559
Slide 133: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 134: gRED oncology development programs -1
gRED oncology development programs -1 Molecule Indication Phase # of patients Status CT Identifier Oncology FPI Q3 2017 R/R multiple myeloma I 355 LPI Q2 2023 NCT03275103 Data presented at ASH 2020-2024 NCT04910568 R/R multiple myeloma I 120 FPI Q2 2021 (CAMMA1) cevostamab (anti-FcRH5 x CD3; RG6160)
Slide 135: gRED oncology development programs -2
gRED oncology development programs -2 Molecule Indication Phase # of patients Status CT Identifier Oncology AR degrader (RG6537)1 mCRPC I ~160 FPI Q2 2023 NCT05800665 NME (RG6468) Solid tumors I 110 FPI Q4 2023 NCT06031441 KRAS G12D inhibitor (RG6620) Solid tumors with KRAS G12D mutations I 410 FPI
Slide 136: gRED neurology, immunology, ophthalmology programs
gRED neurology, immunology, ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Neurology P-CD19 x CD20-ALLO1 CAR-T Multiple Sclerosis I ~60 FPI Q4 2025 NCT07008378 (RG6540) Immunology Cardiac surgery associated acute flizasertib (RG6287, GDC-8264) II 404
Slide 137: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 138: 2025: Pharma Division sales
2025: Pharma Division sales Top 20 products Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Ocrevus 7,010 9 4,874 7 1,451 13 - - 685 21 Hemlibra 4,754 11 2,665 6 1,002 10 377 8 710 38 Vabysmo 4,102 12 2,857 3 741 21 146 22 358 116 Tecentriq 3,566 3 1,640 -
Slide 139: 2025: Pharma Division sales
2025: Pharma Division sales Products launched since 2015 Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Cotellic 46 17 23 42 10 -5 - - 13 4 Alecensa 1,562 6 565 14 262 -6 204 7 531 5 Tecentriq 3,566 3 1,640 -2 878 3 349 -4 699 18 Ocrevus 7,010 9 4,874 7 1
Slide 140: 2025: Pharma Division sales
2025: Pharma Division sales Product sales Pharmaceuticals Division Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Ocrevus 7,010 9 4,874 7 1,451 13 - - 685 21 Hemlibra 4,754 11 2,665 6 1,002 10 377 8 710 38 Vabysmo 4,102 12 2,857 3 741 21 146 22 358 116 Te
Slide 141: Pharma Division CER sales growth in %
Pharma Division CER sales growth1 in % Global top 20 products Q1/24 Q2/24 Q3/24 Q4/24 Q1/25 Q2/25 Q3/25 Q4/25 Ocrevus 8 9 11 7 6 10 6 16 Hemlibra 8 6 14 21 11 22 4 8 Vabysmo 108 81 59 43 18 19 4 7 Tecentriq 1 2 0 -1 0 -1 4 8 Xolair 10 11 12 29 26 41 34 26 Perjeta -3 -1 2 9 -10 -14 -14 -13 Actemra /
Slide 142: 2025: Pharma Division CER sales growth in %
2025: Pharma Division CER sales growth1 in % Top 20 products by region US Europe Japan International Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Ocrevus 3 8 1 17 11 14 12 14 - - - - 16 23 35 11 Hemlibra 0 21 -1 6 7 7 14 12 3 12 11 5 72 60 9 18 Vabysmo 7 10 -4 -1 42 25 9 13 35 28 17 15 101 130 11
Slide 143: CER sales growth (%)
CER sales growth (%) Quarterly development 2024 vs. 2023 2025 vs. 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Pharma Division 2 9 10 12 8 11 7 9 United States 5 6 9 15 6 13 5 9 Europe 11 10 2 10 5 5 5 7 Japan -45 -3 1 1 3 7 6 4 International 12 23 22 11 18 11 11 16 Diagnostics Division 2 8 6 -1 0 0 2 6 Roche Group
Slide 144: Ocrevus
Ocrevus Global sales CER growth Regional sales CER growth CHFbn +9% 7.2 US +7% 7.0 6.8 6.6 Europe +13% 6.4 6.2 6.0 International +21% 5.8 5.6 5.4 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 7,010m ▪ US: Moving into earlier lines displacing orals; SC launch ongoing; #1 in US for both dynamic
Slide 145: Hemlibra
Hemlibra Global sales CER growth Regional sales CER growth CHFbn +11% 5.0 US +6% Europe +10% 4.0 3.0 Japan +8% 2.0 International +38% 1.0 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 4,754m ▪ US: Continued share gains in non-inhibitor patients; US impacted by Q2 buying patterns ▪ EU: Con
Slide 146: Vabysmo
Vabysmo Global sales CER growth Regional sales CER growth CHFbn +12% 5.0 US +3% 4.0 Europe +21% 3.0 2.0 Japan +22% International +116% 1.0 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 4,102m ▪ US: Sales impacted by branded market contraction, continued market share expansion in branded I
Slide 147: Tecentriq
Tecentriq Global sales CER growth Regional sales CER growth CHFbn +3% 4.0 US -2% Europe +3% 3.0 Japan -4% 2.0 1.0 International +18% 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 3,566m ▪ US: Competitive pressure intensifying ▪ EU: Growth despite intensifying competitive pressure ▪ Intern
Slide 148: Xolair
Xolair Global sales CER growth Regional sales CER growth CHFbn +32% 3.5 3.0 2.5 US +32% 2.0 1.5 1.0 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 3,075m ▪ US: Strong food allergy launch with >110k patients treated since launch; Strong CSU performance driving additional growth CER: Con
Slide 149: Perjeta
Perjeta Global sales CER growth Regional sales CER growth CHFbn -13% 4.5 US 0% 4.0 Europe -13% 3.5 3.0 Japan -37% 2.5 2.0 1.5 International -21% 1.0 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 2,968m ▪ US: Increasing conversion to Phesgo ▪ EU: Conversion to Phesgo ▪ Japan: Conversio
Slide 150: Actemra/RoActemra
Actemra/RoActemra ra / RoActemra Global sales CER growth Regional sales CER growth CHFbn -2% 3.0 US -4% Europe -9% 2.5 2.0 Japan +5% 1.5 1.0 International +16% 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 2,470m ▪ US: Decline due to biosimilars ▪ EU: Decline due to biosimilars ▪ Japa
Slide 151: Phesgo
Phesgo Global sales CER growth Regional sales CER growth CHFbn +48% 3.0 US +31% Europe +12% 2.5 2.0 Japan +44% 1.5 1.0 International +172% 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 2,441m ▪ US: Strong growth driven by adjuvant BC; increasing conversion rates from Perjeta+Herceptin
Slide 152: Kadcyla
Kadcyla Global sales CER growth Regional sales CER growth CHFbn +7% 2.5 US +6% Europe -4% 2.0 Japan -3% 1.5 1.0 International +22% 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 2,025m ▪ US: Growth in adjuvant BC compensating for share decline in metastatic BC due to competition ▪ EU:
Slide 153: Evrysdi
Evrysdi Global sales CER growth Regional sales CER growth CHFbn +13% 2.0 US +10% 1.8 Europe +9% 1.6 1.4 1.2 Japan +1% 1.0 0.8 0.6 International +25% 0.4 0.2 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 1,757m ▪ US: Strong uptake across all patient segments; including treatment-naïve pati
Slide 154: Alecensa
Alecensa Global sales CER growth Regional sales CER growth CHFbn +6% 1.8 US +14% 1.6 Europe -6% 1.4 1.2 Japan +7% 1.0 0.8 0.6 International +5% 0.4 0.2 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 1,562m ▪ US: Continued growth; Strong position in 1L ALK+ NSCLC is maintained ▪ EU: Strong
Slide 155: Polivy
Polivy Global sales CER growth Regional sales CER growth CHFbn +38% 1.6 US +28% 1.4 Europe +53% 1.2 Japan +9% 1.0 0.8 0.6 0.4 International +87% 0.2 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 1,470m ▪ US: Growth driven by uptake in 1L DLBCL ▪ EU: Growth driven by uptake in 1L DLBCL ▪ J
Slide 156: MabThera/Rituxan
MabThera/Rituxan Global sales CER growth Regional sales CER growth CHFbn -4% 2.5 US 0% Europe -5% 2.0 Japan -11% 1.5 1.0 International -12% 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 1,251m ▪ US: Biosimilar erosion slowing ▪ EU: Biosimilar erosion bottoms out ▪ International: Biosi
Slide 157: TNKase/Activase
TNKase/Activase Global sales CER growth Regional sales CER growth CHFbn -2% 1.4 1.2 1.0 US -2% 0.8 0.6 0.4 International -11% 0.2 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 1,107m ▪ Spontaneous TNKase use in AIS early time window CER: Constant exchange rates 157
Slide 158: Herceptin
Herceptin Global sales CER growth Regional sales CER growth CHFbn -22% 2.5 US -10% Europe -2% 2.0 Japan -43% 1.5 1.0 International -32% 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 1,028m ▪ US: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Conver
Slide 159: Gazyva
Gazyva Global sales CER growth Regional sales CER growth CHFbn +14% 1.2 US +19% Europe +2% 1.0 0.8 Japan +25% 0.6 0.4 International +15% 0.2 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 986m ▪ US: Strong growth driven by combination therapies in 1L CLL ▪ EU: Growth in 1L CLL partially of
Slide 160: Avastin
Avastin Global sales CER growth Regional sales CER growth CHFbn -17% 2.5 US -17% Europe -16% 2.0 Japan -23% 1.5 1.0 International -14% 0.5 0.0 FY FY FY FY 2022 2023 2024 2025 FY 2025 sales of CHF 973m ▪ US: Ongoing biosimilar erosion ▪ EU: Ongoing biosimilar erosion ▪ Japan: Ongoing biosimilar erosi
Slide 161: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 162: 2025: Diagnostics Division CER growth
2025: Diagnostics Division CER growth By Region and Customer Area (vs. 2024) Reported Restatement Global EMEA North America Asia-Pacific Latin America Global EMEA North America Asia-Pacific Latin America CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % C
Slide 163: 2025: Diagnostics Division quarterly sales and CER growth
2025: Diagnostics Division quarterly sales and CER growth1 By Customer Area (vs. 2024) Reported Restatement Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Core Lab Core Lab Core
Slide 164: 2025: Diagnostics Division regional sales
2025: Diagnostics Division regional sales Growth across regions, offset by APAC Sales YTD CHFm & % of total sales Total CHFm = 13,847 (2% at CER) Growth at CER % +374 1,052 / EMEA +6 -505 8% North America +9 3,386 / 4,965 / +292 of which US +7 24% 36% +116 Asia-Pacific -12 +308 1 of which China -24
Slide 165: Core Lab
Core Lab 2025 vs. 2024 CER growth CHFbn 0% 9.0 8.0 +4% 7.0 +7% 6.0 -3% 5.0 4.0 3.0 2.0 1.0 0.0 FY 2023 FY 2024 FY 2025 Immunodiagnostics Clinical Chemistry Other CER: Constant exchange rates (avg. full year 2024) 165
Slide 166: Molecular Lab
Molecular Lab 2025 vs. 2024 CER growth CHFbn +4% 2.8 +20% 2.4 - 2.0 -11% 1.6 -4% 1.2 -5% -3% 0.8 +3% 0.4 +1% 0.0 FY 2023 FY 2024 FY 2025 Infectious Diseases Blood Screening MD Systems Open Molecular Systems Cervical Cancer Sequencing ML PHCS Other CER: Constant exchange rates (avg. full year 2024);
Slide 167: Near Patient Care
Near Patient Care 2025 vs. 2024 CER growth CHFbn -3% 3.0 -10% 2.5 -5% 2.0 -2% 0% 1.5 +4% 1.0 -22% 0.5 0.0 FY 2023 FY 2024 FY 2025 Clinical Chem. & Immunodiagn. Hospital Glucose Coagulation & Urinalysis BGM POC MDx Other CER: Constant exchange rates (avg. full year 2024); BGM: Blood Glucose Monitorin
Slide 168: Pathology Lab
Pathology Lab 2025 vs. 2024 CER growth CHFbn +14% 1.8 - 1.5 +25% 1.2 +17% +10% 0.9 0.6 0.3 0.0 FY 2023 FY 2024 FY 2025 Advanced Staining Primary Staining PL PHCS Other CER: Constant exchange rates (avg. full year 2024); PHCS: Personalised Healthcare Solutions; PL: Pathology Lab 168
Slide 169: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 170: Exchange rate impact on sales growth
Exchange rate impact on sales growth Negative impact mainly driven by the USD, CNY (APAC), ARS (LATAM), JPY, EUR and TRY (Other) -0.2%p -0.8%p -3.0%p CER CHF sales growth sales growth 2025 +7.2% 2025 vs. vs. 2024 2024 -0.7%p -0.3%p -0.5%p +1.7% CER EUR APAC USD LATAM JPY Other CHF CER: Constant exch
Slide 171: CHF/USD
CHF/USD Monthly averages 0.95 0.85 0% -9% -6% -11% 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 Year-to-date averages 0.95 3% 0.85 -3% -4% -6% 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 171
Slide 172: CHF/USD
CHF/USD 0.95 FY 2025 -6% 0.93 0.91 0.89 0.87 0.85 0.83 0.81 0.79 0.77 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg. full year 2024 avg. full year 2025 monthly avg. 2024 monthly avg. 2025 172
Slide 173: CHF/EUR
CHF/EUR Monthly averages 1.00 0.95 -1% -3% -1% 0% 0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 Year-to-date averages 1.00 0.95 0% -2% -2% -2% 0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 173
Slide 174: CHF/EUR
CHF/EUR 1.00 FY 2025 -2% 0.99 0.98 0.97 0.96 0.95 0.94 0.93 0.92 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg. full year 2024 avg. full year 2025 monthly avg. 2024 monthly avg. 2025 174
Slide 175: Average CHF exchange rates
Average CHF exchange rates FY 2025 FY 2024 FY 2025 vs. FY 2024 USD 0.83 0.88 -6% EUR 0.94 0.95 -2% JPY 0.56 0.58 -4% -6% -4% -2% 0% 175
Slide 176: Exchange rate impact on sales growth
Exchange rate impact on sales growth 2025: Negative impact of USD, CNY, JPY and EUR Development of average exchange rates versus prior year period Q1 HY YTD Sep FY CHF / USD 2.9% -2.9% -4.4% -5.5% CHF / EUR -0.3% -2.1% -1.9% -1.6% CHF / JPY 0.1% -0.6% -2.6% -4.4% CHF / CNY 1.7% -3.3% -4.6% -5.3% Dif
Slide 177: Exchange rate impact on sales growth
Exchange rate impact on sales growth 2025: Negative impact of JPY, USD, CNY and EUR Development of average exchange rates versus prior year period Q1 Q2 Q3 Q4 CHF / USD 2.9% -8.5% -7.6% -8.9% CHF / EUR -0.3% -3.8% -1.7% -0.6% CHF / JPY 0.1% -1.5% -6.6% -9.9% CHF / CNY 1.7% -8.2% -7.4% -7.5% Differen
Slide 178: Appendix contents
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 179: 2025: Significant milestones achieved
2025: Significant milestones achieved Compound Indication Milestone Itovebi + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval / (US/EU) Lunsumio SC 3L+ FL US/EU approval Elevidys DMD EU approval Regulatory Gazyva Lupus nephritis US/EU approval Susv
Slide 180: Diagnostics key launches 2025
Diagnostics key launches 2025 Area Product Description Market Status Elecsys® pTau 181 Non-invasive blood-based biomarker to enable earlier detection and rule out amyloid pathology CE Elecsys® Troponin-T hs High-sensitive test with greater precision at lower measurement ranges, enabling HCPs to conf
Slide 181: Proposed exchange of Genussscheine for participation certificates
Roche’s Board of Directors proposes exchange of Genussscheine for participation certificates (Partizipationsscheine) AGM 2026 ex-Date Payment Date Listing Date Settlement Date 10 Mar 2026 12 Mar 2026 16 Mar 2026 17 Mar 2026 19 Mar 2026 AGM to vote on: Approval of Genussscheine and Payment of dividen
Slide 182: Doing now what patients need next
Doing now what patients need next